JPRN-jRCT2080221222未知3 期
Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar Pollinosis
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •1)Patients with specific IgE against cedar pollen CAP class 3 or more
- •2)Patients with clinical history of cedar pollinosis in cedar pollen dispersion season
排除标准
- •1)Patients with complication of nose disease that may interfere with evaluation (nasal polyps, deviation of nasal septum), chronic sinusitis, etc
- •2)Patients who have developed asthmatic attack within 5 years before the pre-treatment observation visit
- •3)Patients who have received specific immunotherapy for cedar pollinosis in history
- •4)Patients with during pregnancy, breast-feeding, possibility of pregnancy or wish to pregnancy during this clinical study period
- •5)Patients who have participated in any other clinical study or clinical research (including medical equipment study) within 12 weeks before the pre-treatment observation visit
研究者
相似试验
未知
2 期
Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced AsthmaJPRN-jRCT2080221805TORII PHARMACEUTICAL CO., LTD.900
未知
2 期
Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced RhinitisHDM-induced rhinitisJPRN-jRCT2080221806TORII PHARMACEUTICAL CO., LTD.900
进行中（未招募）
1 期
Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnosed or undiagnosed allergic diseaseRecurrent airway inflammation in children with impaired cellular immunity.EUCTR2013-003303-18-PLGedeon Richter Polska Sp. z o. o.
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-FIMSD Finland20,300
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age - ZOSTAVAX™ in Subjects 50 to 59 Years of AgeMedDRA version: 9.1Level: LLTClassification code 10019974Term: Herpes zosterHerpes ZosterEUCTR2007-004020-20-DEMerck & Co., Inc.20,300